Article (Scientific journals)
Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises.
Kanapeckaitė, Austė; Mažeikienė, Asta; Geris, Liesbet et al.
2022In Biophysical Chemistry, 290, p. 106891
Peer Reviewed verified by ORBi
 

Files


Full Text
biophyschem_2022.pdf
Author postprint (4.87 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
MicroRNAs; Pharmaceutical Preparations; Small Molecule Libraries; Humans; Pandemics; COVID-19 Drug Treatment; COVID-19; Cheminformatics; Clinical trials; Drug repurposing; Machine learning; Systems biology
Abstract :
[en] The COVID-19 pandemic created an unprecedented global healthcare emergency prompting the exploration of new therapeutic avenues, including drug repurposing. A large number of ongoing studies revealed pervasive issues in clinical research, such as the lack of accessible and organised data. Moreover, current shortcomings in clinical studies highlighted the need for a multi-faceted approach to tackle this health crisis. Thus, we set out to explore and develop new strategies for drug repositioning by employing computational pharmacology, data mining, systems biology, and computational chemistry to advance shared efforts in identifying key targets, affected networks, and potential pharmaceutical intervention options. Our study revealed that formulating pharmacological strategies should rely on both therapeutic targets and their networks. We showed how data mining can reveal regulatory patterns, capture novel targets, alert about side-effects, and help identify new therapeutic avenues. We also highlighted the importance of the miRNA regulatory layer and how this information could be used to monitor disease progression or devise treatment strategies. Importantly, our work bridged the interactome with the chemical compound space to better understand the complex landscape of COVID-19 drugs. Machine and deep learning allowed us to showcase limitations in current chemical libraries for COVID-19 suggesting that both in silico and experimental analyses should be combined to retrieve therapeutically valuable compounds. Based on the gathered data, we strongly advocate for taking this opportunity to establish robust practices for treating today's and future infectious diseases by preparing solid analytical frameworks.
Disciplines :
Engineering, computing & technology: Multidisciplinary, general & others
Author, co-author :
Kanapeckaitė, Austė;  AK Consulting, Laisvės g. 7, LT 12007 Vilnius, Lithuania. Electronic address:
Mažeikienė, Asta;  Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine,
Geris, Liesbet  ;  Université de Liège - ULiège > Département d'aérospatiale et mécanique > Génie biomécanique
Burokienė, Neringa;  Clinics of Internal Diseases, Family Medicine and Oncology, Institute of Clinical
Cottrell, Graeme S;  University of Reading, School of Pharmacy, Hopkins Building, Reading RG6 6UB,
Widera, Darius;  University of Reading, School of Pharmacy, Hopkins Building, Reading RG6 6UB,
Language :
English
Title :
Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises.
Publication date :
November 2022
Journal title :
Biophysical Chemistry
ISSN :
0301-4622
Publisher :
Elsevier, Nl
Volume :
290
Pages :
106891
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright © 2022 Elsevier B.V. All rights reserved.
Available on ORBi :
since 06 July 2023

Statistics


Number of views
49 (1 by ULiège)
Number of downloads
52 (0 by ULiège)

Scopus citations®
 
1
Scopus citations®
without self-citations
1
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi